CAPTRUST Financial Advisors
PACB icon

CAPTRUST Financial Advisors’s Pacific Biosciences PACB Stock Holding History

CAPTRUST Financial Advisors’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.5K Buy
44,320
+1,361
+3% +$2.44K ﹤0.01% 2883
2025
Q4 		$80.3K Buy
+42,959
New +$82.5K ﹤0.01% 2635
2024
Q1 		– Sell
-13,603
Closed -$133K – 2503
2023
Q4 		$133K Buy
13,603
+736
+6% +$6.02K ﹤0.01% 2484
2023
Q3 		$107K Buy
12,867
+1,276
+11% +$14.6K ﹤0.01% 2422
2023
Q2 		$154K Buy
+11,591
New +$141K ﹤0.01% 2321
2022
Q3 		– Sell
-1,553
Closed -$7K – 3420
2022
Q2 		$7K Sell
1,553
-390
-20% -$2.37K ﹤0.01% 3938
2022
Q1 		$18K Buy
1,943
+919
+90% +$10.6K ﹤0.01% 3458
2021
Q4 		$21K Sell
1,024
-1,428
-58% -$34.5K ﹤0.01% 3256
2021
Q3 		$63K Buy
2,452
+144
+6% +$4.27K ﹤0.01% 2429
2021
Q2 		$81K Sell
2,308
-327
-12% -$9.51K ﹤0.01% 2187
2021
Q1 		$88K Buy
+2,635
New +$92.2K ﹤0.01% 2050

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CAPTRUST Financial Advisors's PACB Position: Q1 2026 in Review

CAPTRUST Financial Advisors increased its Pacific Biosciences (PACB) stake by 3.2% in Q1 2026, buying an estimated $2.44K and bringing the position to 44,320 shares worth $58.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2883.

CAPTRUST Financial Advisors first reported a position in PACB in Q1 2021 and has held it in 11 quarters since. The position peaked at $154K in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • CAPTRUST Financial Advisors held 44,320 shares of Pacific Biosciences worth $58.5K as of Q1 2026.
  • CAPTRUST Financial Advisors bought 1,361 Pacific Biosciences shares in Q1 2026, an estimated $2.44K.
  • Pacific Biosciences made up ﹤0.01% of CAPTRUST Financial Advisors's portfolio in Q1 2026, its #2883 holding.
  • CAPTRUST Financial Advisors first reported a position in Pacific Biosciences in Q1 2021 and has held it in 11 quarters since.
  • CAPTRUST Financial Advisors's Pacific Biosciences position peaked at $154K in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q1 2026, filed 15 May 2026.